Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Denali Therapeutics Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 202
- +4 vs. Q4 2022
- Shares held
- 108.0M
- +2.13M (+2.0%) vs. Q4 2022
- Total value
- $2.49B
- −$456.7M (−15.5%) vs. Q4 2022
- New holders
- 26
- 92 more added
- Sold out
- 22
- 51 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 294 | $4.00B |
| Q1 2026 | 269 | $2.82B |
| Q4 2025 | 250 | $2.50B |
| Q3 2025 | 240 | $1.97B |
| Q2 2025 | 231 | $1.93B |
| Q1 2025 | 222 | $1.85B |
| Q4 2024 | 224 | $2.61B |
| Q3 2024 | 217 | $3.69B |
| Q2 2024 | 203 | $2.88B |
| Q1 2024 | 211 | $2.51B |
| Q4 2023 | 209 | $2.47B |
| Q3 2023 | 195 | $2.24B |
| Q2 2023 | 203 | $3.18B |
| Q1 2023 | 202 | $2.49B |
| Q4 2022 | 199 | $2.94B |
| Q3 2022 | 200 | $2.84B |
| Q2 2022 | 188 | $2.73B |
| Q1 2022 | 190 | $2.79B |
| Q4 2021 | 213 | $3.80B |
| Q3 2021 | 214 | $4.28B |
| Q2 2021 | 210 | $6.32B |
| Q1 2021 | 218 | $4.60B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Denali Therapeutics Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 10,118,493 | $233.1M | 0.01% | +171,395+1.7% | Added |
| Baillie Gifford & Co | 15,352,111 | $353.7M | 0.32% | +232,637+1.5% | Added |
| Man Group plc | 0 | $0 | 0.00% | −142,929−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −64,400−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −61,096−100.0% | Sold out |
| Bridgewater Associates, LP | 0 | $0 | 0.00% | −14,970−100.0% | Sold out |
| Gotham Asset Management, LLC | 0 | $0 | 0.00% | −13,029−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,306−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,231−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −10,751−100.0% | Sold out |
| Mackenzie Financial Corp | 0 | $0 | 0.00% | −7,959−100.0% | Sold out |
| Ally Bridge Group (NY) LLC | 0 | $0 | 0.00% | −4,479−100.0% | Sold out |
| Exchange Traded Concepts, LLC | 0 | $0 | 0.00% | −2,584−100.0% | Sold out |
| Sandia Investment Management LP | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −1,313−100.0% | Sold out |
| High Net Worth Advisory Group LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Comerica Securities,inc. | 0 | $0 | 0.00% | −225−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −119−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Baker Avenue Asset Management, LP | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| VitalStone Financial, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| HealthInvest Partners AB | – | – | – | – | Not filed |